Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020110118 - COMPOSITIONS PERMETTANT LE TRAITEMENT DE LA SYMPHYSIOLYSE

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

1. A composition comprising an effective amount of a local anesthetic agent or a salt thereof, for use in subcutaneous administration to a patient suffering from girdle pain or symphysiolysis.

2. The composition according to claim 1 wherein the composition is for use in blocking neural transmission at the superficial inguinal ring or canal, or ASIS region.

3. The composition according to claim 1 or 2 for use in administration to the inguinal region, or ASIS region.

4. The composition according to any one of the previous claims for use in administration to the left inguinal region, the right inguinal region, the superior inguinal region or any combination of the superior, left and right inguinal regions, or ASIS region.

5. The composition according to any one of the previous claims wherein the patient is a pregnant woman.

6. The composition according to any one of the previous claims wherein the patient is in the 30th or greater week of pregnancy.

7. The composition according to any one of claims 1-4 wherein the patient is post pregnancy.

8. The composition according to any one of the previous claims wherein the local anesthetic agent or salt thereof comprises an intermediate-acting or long-acting local anesthetic.

9. The composition according to claim 8 comprising an intermediate-acting and a long-acting local anesthetic or salt thereof.

10. The composition according to any one of the previous claims wherein the local anesthetic is selected from a group consisting of amino-ester anesthetics and amino- amide anesthetic and salts thereof.

11. The composition according to claim 10 wherein the local anesthetic is an amino- amide anesthetic or a salt thereof.

12. The composition according to any one of the previous claims wherein the composition further comprises a vasoconstrictor.

13. The composition according to claim 12 wherein the vasoconstrictor is epinephrine.

14. The composition according to any one of the previous claims further comprising a pH adjusting moiety.

15. The composition according to claim 14 wherein the pH adjusting moiety is sodium bicarbonate.

16. The composition according to any one of the previous claims further comprising a viscosity modifying agent.

17. The composition according to claim 16 wherein the specific gravity is above 1.02.

18. The composition according to claim 16 or 17 wherein the viscosity modifying agent is present in the composition in an amount of between 1% and 50%.

19. The composition according to any one of the previous claims wherein the local anesthetic agent is lidocaine.

20. The composition according to any one of the previous claims wherein the local anesthetic agent is bupivicaine.

21. The composition according to any one of the previous claims for administration in the region between the symphysis pubis and the anterior superior iliac spine.

22. The composition according to any one of the previous claims wherein the administration provides nerve blocking effect for between 6 and 24 hours.

23. A single-use container comprising a composition according to any one of the previous claims.

24. The single-use container according to claim 23 in the form of a prefilled syringe.

25. The single-use container according to claim 23 in the form of a cartridge for use in combination with a pump for subcutaneous administration.

26. The single-use container according to any one of claims 23 to 25 comprising a volume of composition of between 1 and 20 ml.

27. The single-use container according to claim 26 comprising a volume of composition of between 2.5 and 20 ml.

28. The single-use container according to claim 23 comprising between 5 and 400 mg of a local anesthetic agent.

29. The single-use container according to claim 23 comprising between 50 and 200 mg of a local anesthetic agent.

30. The single-use container according to any one of claims 23 to 29 comprising between 10% and 50% of the maximal dose of the anesthetic.

31. The single-use container according to any one of claims 23 to 29 comprising between 50% and 100% of the maximal dose of the anesthetic.

32. A kit comprising two or more single-use containers according to any one of claims 23 to 29 .

33. The kit according to claim 32 further comprising written instructions, instructing to administer to a patient suffering from girdle pain or symphysiolysis.

34. The kit according to claim 33 wherein the instructions direct a user of the kit to administer a composition to the inguinal region.

35. The kit according to any one of claims 32 to 34 comprising between 2 and 30 single-use containers.

36. The kit according to any one of claims 32 to 35 comprising at least two single-use containers, wherein at least one single-use container comprises a first dose and at least one single-use container in the kit comprises a second dose, and wherein the first dose is different than the second dose.

37. The kit according to claim 36 wherein the first dose is a test dose and the second dose is a treatment dose.

38. A composition comprising an effective amount of a local anesthetic agent or a salt thereof, for use in subcutaneous administration to a patient for diagnosis of pelvic girdle pain or symphysiolysis.

39. The composition according to claim 38 wherein the composition is for use in blocking neural transmission at the superficial inguinal ring or canal or ASIS region.

40. The composition according to claim 38 or 39 for use in administration to the inguinal region or ASIS region.

41. A method for treatment of a patient suffering from girdle pain or symphysiolysis comprising administering to the patient a composition comprising an effective amount of a local anesthetic agent or a salt thereof, via subcutaneous administration.

42. The method according to claim 41 wherein the composition blocks neural transmission at the superficial inguinal ring or canal, or ASIS region.

43. The method according to claim 41 or 42 wherein the composition is administered to the inguinal region, or ASIS region.

44. The method according to any one of claims 41-43 wherein the composition is administered to the left inguinal region, the right inguinal region, the superior inguinal region or any combination of the superior, left and right inguinal regions, or ASIS region.

45. The method according to any one of the claims 41-44 wherein the patient is a pregnant woman.

46. The method according to any one of the claims 41-45 wherein the patient is in the 30th or greater week of pregnancy.

47. The method according to any one of claims 41-44 wherein the patient is post pregnancy.

48. The method according to any one claims 41-47 wherein the local anesthetic agent or salt thereof comprises an intermediate- acting or long-acting local anesthetic.

49. The method according to claim 48 comprising an intermediate-acting and a long- acting local anesthetic or salt thereof.

50. The method according to any one of claims 41-49 wherein the local anesthetic is selected from a group consisting of amino-ester anesthetics and amino-amide anesthetic and salts thereof.

51. The method according to claim 50 wherein the local anesthetic is an amino-amide anesthetic or a salt thereof.

52. The method according to any one of the claims 41-51 wherein the composition further comprises a vasoconstrictor.

53. The method according to claim 52 wherein the vasoconstrictor is epinephrine.

54. The method according to any one of claims 41-53 wherein the composition further comprises a pH adjusting moiety.

55. The method according to claim 54 wherein the pH adjusting moiety is sodium bicarbonate.

56. The method according to any one of claims 41-55 further comprising a viscosity modifying agent.

57. The method according to claim 56 wherein the specific gravity is above 1.02.

58. The method according to claim 56 or 57 wherein the viscosity modifying agent is present in the composition in an amount of between 1% and 50%.

59. The method according to any one of claims 41-58 wherein the local anesthetic agent is lidocaine.

60. The method according to any one of claims 41-59 wherein the local anesthetic agent is bupivicaine.

61. The method according to any one of claims 41-60 wherein the composition is administered in the region between the symphysis pubis and the anterior superior iliac spine.

62. The method according to any one of claims 41-61 wherein the composition is provided in a single-use container.

63. The method according to claim 62 wherein the composition is in the form of a prefilled syringe.

64. The method according to claim 62 wherein the composition is in the form of a cartridge for use in combination with a pump for subcutaneous administration.

65. The method according to any one of claims 62 to 64 wherein the container comprises a volume of composition of between 1 and 20 ml.

66. The method according to claim 65 wherein the container comprises a volume of composition of between 2.5 and 20 ml.

67. The method according to any one of claims 41 to 66 wherein the patient is administered between 5 and 400 mg of a local anesthetic agent.

68. The method according to claim 67 wherein the patient is administered between 50 and 200 mg of a local anesthetic agent.

69. The method according to any one of claims 41 to 68 wherein the patient is administered between 10% and 50% of the maximal dose of the anesthetic.

70. The method according to any one of claims 41 to 68 wherein the patient is administered between 50% and 100% of the maximal dose of the anesthetic.

71. The method according to any one of claims 41 to 71 wherein the administration provides nerve blocking effect for between 6 and 24 hours.

72. A kit comprising a composition comprising an effective amount of a local anesthetic agent or a salt thereof, and instructions, the instructions directing the patient suffering from girdle pain or symphysiolysis to inject the composition via subcutaneous administration.

73. The kit according to claim 72, comprising two or more single-use containers, each container comprising a composition comprising an effective amount of a local anesthetic agent or a salt thereof.

74. The kit according to claim 72 or 73 wherein the instructions direct a user of the kit to administer a composition to the inguinal region.

75. The kit according to either of claims 73 or 74 comprising between 2 and 30 single use containers.

76. The kit according to any one of claims 73 to 75 comprising at least two single-use containers, wherein at least one single-use container comprises a first dose and at least one single-use container in the kit comprises a second dose, and wherein the first dose is different than the second dose.

77. The kit according to claim 76 wherein the first dose is a test dose and the second dose is a treatment dose.

78. A method for diagnosis of a patient suffering from girdle pain or symphysiolysis comprising administering to the patient a composition comprising an effective amount of a local anesthetic agent or a salt thereof, via subcutaneous administration, and determining if the patient suffers from a symptom of girdle pain or symphysiolysis.

79. The method according to claim 78 wherein the composition is administered to block neural transmission at the superficial inguinal ring or canal or ASIS region.

80. The method according to claim 78 or 79 wherein the composition is administered to the inguinal region or ASIS region.